Prophylactic bromocriptine treatment during pregnancy in women with macroprolactinomas: report of 13 pregnancies.
Ten women with a macroprolactinoma had prophylactic bromocriptine treatment during 13 pregnancies in the second and third trimesters. One patient had signs of tumour enlargement during the first trimester, but none of them showed tumour enlargement during prophylactic bromocriptine treatment. Prolactin levels were reduced in both maternal and cord sera, but they were normal in amniotic fluid. All pregnancies progressed to term. Thirteen healthy infants were born without congenital malformations and growth and psychomotor development were normal during the follow-up period (7 months to 5 years). The safety of bromocriptine treatment during pregnancy is discussed and our current policy of management of patients with prolactinomas is outlined.
D000328:Adult; D000653:Amniotic Fluid / Q000032:analysis; D001971:Bromocriptine / Q000627:therapeutic use*; D002675:Child, Preschool; D005260:Female; D005312:Fetal Blood / Q000032:analysis; D006801:Humans; D007231:Infant, Newborn; D008297:Male; D010911:Pituitary Neoplasms / Q000097:blood / Q000188:drug therapy / Q000378:metabolism*; D011247:Pregnancy; D011252:Pregnancy Complications, Neoplastic / Q000097:blood / Q000188:drug therapy / Q000378:metabolism*; D011388:Prolactin / Q000097:blood / Q000378:metabolism*
D001971:Bromocriptine; D011388:Prolactin